QUEST PHARMATECH INC (QPT.CA) Stock News

Canada - TSX Venture Exchange - TSX-V:QPT - CA74836M1068 - Common Stock

0.04 CAD

0 (-11.11%)

Last: 11/25/2025, 7:00:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

QPT.CA Latest News, Press Relases and Analysis

All

Press Releases

3 months ago - By: Quest PharmaTech Inc.

Quest PharmaTech Announces Results from AGM

6 months ago - By: Quest PharmaTech Inc.

Quest PharmaTech Announces Opposition to OQPBIOM's Acquisition of AdBioTech

6 months ago - By: Quest PharmaTech Inc.

Quest PharmaTech Provides Corporate Update

a year ago - By: Quest PharmaTech Inc.

Quest PharmaTech Announces Results from AGM

4 years ago - By: Quest PharmaTech Inc.

OncoQuest Pharmaceuticals Inc. Announces First Patient Enrolled in Each of Two Investigator Initiated Clinical Trials of Oregovomab in Combination Therapy for the Treatment of Recurrent Ovarian Cancer

4 years ago - By: Quest PharmaTech Inc.

Quest PharmaTech announces two presentations by OncoQuest Pharmaceuticals, Inc. at the 2021 Annual Meeting of the American Association of Clinical Oncologists

5 years ago - By: Quest PharmaTech Inc.

Quest Announces that OncoQuest Pharmaceuticals Inc. Doses First Patient in Phase 3 Clinical Trial, FLORA-5, of Company's Lead Investigational Drug, Oregovomab, in Frontline Ovarian Cancer and appoints Dr. Sunil Gupta as Chief Medical Officer

5 years ago - By: Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions

News Image

IIROC Trading Resumption - QPT

6 years ago - By: Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions

News Image

UPDATE - IIROC Trading Halt - QPT

6 years ago - By: Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions

News Image

IIROC Trading Halt - QPT

6 years ago - By: OncoQuest Inc.

News Image

OncoQuest Announces Publication of Two Reports Related to Oregovomab Phase 2 Clinical Trial, the Company's Lead Investigational Drug in Frontline Ovarian Cancer

6 years ago - By: OncoQuest Inc.

News Image

OncoQuest Announces a U.S.$50 Million Investment by KOSDAQ listed Dual Industrial Co. Ltd.

6 years ago - By: OncoQuest Inc.

News Image

OncoQuest Receives "Notice of Allowance" for Patent Protection of the Administration Schedule of Oregovomab and Chemotherapy for Stage III-IV Ovarian Cancer Patients